Remove Insulin Remove Marketing Remove Pharma Companies
article thumbnail

Why the drug pricing debate is focused on insulin

pharmaphorum

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing. In the US, approximately 37.3

Insulin 130
article thumbnail

Arecor hopes London stock market float will raise profile of insulin products

pharmaphorum

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. The initial therapeutic focus is diabetes, with three insulin-based products in development.

Insulin 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Delveinsight

However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease. Multiple Sclerosis (MS).

article thumbnail

Pharma, patient advocates clash over Inflation Reduction Act

Pharmaceutical Technology

At the core of the debate was a new provision allowing the US Centers for Medicare & Medicaid Services (CMS) to negotiate prices with pharmaceutical companies for a select number of drugs. While negotiating drug prices is common practice in other major markets, CMS had not previously held the legal authority to do so.

Insulin 130
article thumbnail

How the patient voice is becoming vital for drug approval

pharmaphorum

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Drugs 105
article thumbnail

Arecor heads for London Stock Exchange with drug reformulation strategy

pharmaphorum

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients. .

Insulin 52
article thumbnail

Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes

pharmaphorum

In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. This will also mean the industry needs to think about how HCPs will want to interact with pharma companies. “If